Neurotoxicity of Spinal Anesthesia With Ropivacaine and Bupivacaine
Status:
Unknown status
Trial end date:
2019-12-31
Target enrollment:
Participant gender:
Summary
Consenting patients, scheduled for orthopaedic surgery under spinal anesthesia will be
randomly assigned (1:1) to receive ropivacaine or bupivacaine as a single shot before the
start of surgery, followed by bolus doses of the same local anesthetic as required during the
surgery, and continuous infusion of the same local anesthetic for 24 hours postoperatively.
Primary Outcome Measures: Evaluation of changes in concentrations of glutamate in the
cerebrospinal fluid and in the blood. Secondary outcomes: : Evaluation of changes in
concentrations of selected mediators of inflammatory response (IL-1β, IL-6, TNF and others)
and selected chemokines as markers of the glia damage.
Hemodynamic stability during the surgery, and efficacy of postoperative analgesia will be
also evaluated.
Phase:
Phase 4
Details
Lead Sponsor:
University of Rzeszow
Collaborator:
Department of Anesthesiology, Intensive Therapy, District Hospital No2 in Rzeszow